Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $12.20

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $12.20.

Several brokerages have recently issued reports on INO. StockNews.com raised Inovio Pharmaceuticals to a “sell” rating in a research report on Friday, March 21st. Royal Bank of Canada decreased their price objective on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a report on Wednesday, March 19th. HC Wainwright reiterated a “neutral” rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. Finally, JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th.

Inovio Pharmaceuticals Stock Performance

Shares of INO stock opened at $1.73 on Wednesday. The company has a market capitalization of $45.15 million, a price-to-earnings ratio of -0.43 and a beta of 0.92. Inovio Pharmaceuticals has a 52-week low of $1.68 and a 52-week high of $14.75. The company has a 50-day simple moving average of $2.03 and a two-hundred day simple moving average of $3.55.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.18. The business had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.03 million. On average, sell-side analysts forecast that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INO. Geode Capital Management LLC raised its position in shares of Inovio Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after purchasing an additional 38,833 shares during the period. Barclays PLC raised its holdings in Inovio Pharmaceuticals by 282.6% during the 3rd quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock valued at $197,000 after acquiring an additional 25,116 shares during the period. FMR LLC raised its holdings in Inovio Pharmaceuticals by 370.1% during the 3rd quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 21,462 shares during the period. State Street Corp lifted its position in shares of Inovio Pharmaceuticals by 11.7% during the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after acquiring an additional 51,414 shares in the last quarter. Finally, Green Alpha Advisors LLC boosted its holdings in shares of Inovio Pharmaceuticals by 103.2% in the fourth quarter. Green Alpha Advisors LLC now owns 65,446 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 33,232 shares during the period. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.